Google快讯 - lung cancer

	lung cancer 实时更新 ⋅ 2025年3月29日
	新闻
	A Case of First-Line Treatment for Rare ROS1 Fusion Mutation Lung Adenocarcinoma with ... Frontiers The incidence of the ROS1 fusion mutation (ROS proto-oncogene 1) in non-small cell lung cancer (NSCLC) is approximately 1-2%. 标记为不相关
	NCCN 2025: Immune Checkpoint Inhibitors Expand Treatment Options for Early-Stage NSCLC Pharmacy Times PD-L1 immune checkpoint inhibitors are now standard for early-stage non-metastatic non-small cell lung cancer (NSCLC), with neoadjuvant, adjuvant, ... 标记为不相关
	Projected Cancer Trends Highlight Urgent Need for Prevention - YouTube YouTube ... lung cancer and cervical cancer for women, and lung cancer, liver cancer, gallbladder cancer, and non-Hodgkin lymphoma for men. Again, this is a ... 标记为不相关
	Merck seeks FDA approval for subcutaneous pembrolizumab - Indian Pharma Post Indian Pharma Post These results was presented at the European Lung Cancer Congress (ELCC) 2025 and published simultaneously in Annals of Oncology. The study met its ... 标记为不相关
	FDA Approves Expanded Label of Novartis' Prostate Cancer Treatment, Pluvicto Applied Clinical Trials ... Lung Cancer. March 26th 2025 · Reaching Diverse Patient Populations With Personalized Treatment Methods. January 20th 2025 · Results of Phase III ... 标记为不相关
	Onvida Health Introduces Cutting-Edge Ion Robot for Early Lung Cancer Detection - KYMA KYMA ... lung cancer care in Yuma. The hospital has introduced the Ion robotic system, a groundbreaking tool designed to improve the detection of small lung ... 标记为不相关
	Genelux Corporation Reports Fourth Quarter and Full Year - GlobeNewswire GlobeNewswire ... lung cancer. The trial is co-sponsored by the Company and its licensing partner, Newsoara BioPharma Co., Ltd. (Newsoara). Systemic administration ... 标记为不相关
	Cars, Cancer Screenings and Brandon Graham Cruise the Lehigh Valley Auto Show Lehigh Valley Health Network ... cancer will be diagnosed. It's the second-most-common cancer among men, after lung cancer, according to the American Cancer Society. LVHN ... 标记为不相关
	CHMP Recommends Approval of Subcutaneous Nivolumab in Multiple Solid Tumors OncLive The EFS benefit was similar per investigator assessment (HR, 0.56; 95% CI, 0.41-0.76). Read more. Global OncologyLung CancerImmuno-Oncology. 标记为不相关
	Obituary: William (Bill) Forest Stratton - KRTV KRTV Bill passed after having fought hard against an aggressive form of lung cancer. Bill spent his early years in Great Falls and Havre MT, before ... 标记为不相关
查看更多结果 | 修改此快讯

您收到此电子邮件是因为您订阅了Google快讯。 退订 | 查看您所有的快讯

以RSS Feed的形式接收此快讯

发送反馈